Reference Product [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-09-25 00:53 (4269 d 23:33 ago) – Posting: # 11554
Views: 6,039

Hi Tina,

❝ Instead of MRP/DCP, if the product were to be marketed only in one country and if the innovator isnt available in that country, are we justified in showing BE with the generic which is available in the country (which has showed BE with the innovator?) and is available in the market for more than 8 years.


No. By definition BE is based on a comparative bioavailability study where the reference is the innovator. See this old slide. You have two generics, the first test is BE to the innovator but the second test is not. If you would use the first test as the reference, test 2 would be “bioequivalent”.

❝ If the innovator product is a capsule and the proposed test are tablets…


In the EU you can show BE for pharmaceutical alternatives as well. No problem.

❝ …if innovator in not available in the proposed country, doing a BE study in the existing generic (tablets ) will reduce formulation (capsule vs tablet) associated any change in the release of the active from the formulation.


No way (see above). Even if you want to go for a national application, you can use a reference with a MA in any country of the EEA. If the innovator is not marketed in any member state, bad luck.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,682 registered users;
34 visitors (0 registered, 34 guests [including 21 identified bots]).
Forum time: 00:27 CEST (Europe/Vienna)

Being really good at C++ is like being really good
at using rocks to sharpen sticks.    Thant Tessman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5